Skip to main content

Advertisement

SpringerLink
Log in

The Clonal Evolution and Therapeutic Approaches of Lung Cancer

  • Review Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

According to the World Cancer Research Foundation, the newly diagnosed annual lung cancer cases all over the world are alarmingly high at 12.5 %. It also shows the highest mortality rate among all the cancer types. Nearly 225,000 new lung cancer patients are reported annually in the USA. The lung cancer cells also have very fast growth rates. As a result of this rapid proliferation rate, the lung cancer cells are sensitive to the available therapeutics like the radiation, surgical, or chemo therapy. Notwithstanding all the advances in the field of tumor biology, the mortality rate with lung cancer has remained significantly high. Precise and early diagnosis of the disease can be an important step in the proper and successful setting up of the treatment modalities. There are no comprehensive reviews available that discusses all the basic and updated aspects of lung cancer. This review focuses on the basic aspects of lung cancer like the etiology, risk factors, and clonal evolution. Exposure to smoking comes up as a single major environmental cause of the disease. The classification of lung cancer has also been discussed in detail based on immunohistochemistry. The existing therapeutic approaches as well as the upcoming modern day interventions have been discussed with their pros and cons. Recent techniques like molecular profiling can prove to be highly beneficial if properly standardized. With such advancements in therapy in conjunction with the updated diagnostics, there is a real hope in the treatment of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Travis, W. D., Brambilla, E., Muller-Hermelink, H. K., & Harris, C. C. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart, World Health Organization Classification of Tumours. Lyon: IARC.

  2. Nicholson, A. G., Gonzalez, D., Shah, P., Pynegar, M. J., Deshmukh, M., Rice, A., et al. (2010). Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of Mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. Journal of Thoracic Oncology, 5, 436–441.

    Article  PubMed  Google Scholar 

  3. Peto, R., Lopez, A. D., Boreham, J., Thun, M., & Heath, C, Jr. (1994). Mortality from smoking in developed countries 1950–2000 (Vol. 143, p. 658). Indirect Estimates from National Vital Statistics: Oxford University Press, New York.

    Google Scholar 

  4. Sridhar, S. S., Seymour, L., & Shepherd, F. A. (2003). Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncology, 4, 397–406.

    Article  CAS  PubMed  Google Scholar 

  5. Sawyers, C. L. (2002). Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell, 1, 413–415.

    Article  CAS  PubMed  Google Scholar 

  6. Hollinshead, A., Stewart, T. H. M., Takita, H., Dalbow, M., & Concannon, J. (1987). Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer, 60, 1249–1262.

    Article  CAS  PubMed  Google Scholar 

  7. Mazzone, P. (2012). Preoperative evaluation of the lung resection candidate. Cleveland Clinic Journal of Medicine, 79, eS17–eS22.

    PubMed  Google Scholar 

  8. Beane, J., Sebastiani, P., Whitfield, T. H., Steiling, K., Dumas, Y. M., Lenburg, M. E., et al. (2008). A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prevention Research, 1, 56–64.

    Article  PubMed  Google Scholar 

  9. Yildiz, P. B., Shyr, Y., Rahman, J. S., Wardwell, N. R., Zimmerman, L. J., Shakhtour, B., et al. (2007). Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. Journal of Thoracic Oncology, 2, 893–901.

    Article  PubMed  Google Scholar 

  10. Saracci, R., & Boffetta, P. (1994). Interactions of tobacco smoking and other causes of lung cancer. In J. M. Samet (Ed.), Epidemiology of lung cancer (pp. 465–493). New York, NY: Marcel Dekker.

    Google Scholar 

  11. Samet, J. M., & Cohen, A. J. (1999). Air pollution and lung cancer. In S. Holgate, J. M. Samet, H. S. Koren, et al. (Eds.), Air pollution and health (pp. 841–864). San Diego, CA: Academic Press.

    Chapter  Google Scholar 

  12. Willett, W. C. (1995). Diet, nutrition, and avoidable cancer. Environmental Health Perspectives, 103(suppl 8), 165–170.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Samet, J. M. (1995). Lung cancer. In P. Greenwald, B. S. Kramer, & D. L. Weed (Eds.), Cancer prevention and control (pp. 561–584). New York, NY: Marcel Dekker.

    Google Scholar 

  14. Health effects of exposure to radon (BEIR VI) (1999). Washington, DC: National Academy Press, National Research Council, Committee on Health Risks of Exposure to Radon, Board on Radiation Effects Research, Commission on Life Sciences.

  15. Spira, A., Beane, J., Shah, V., Liu, G., Schembri, F., Yang, X., et al. (2004). Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proceedings of the National Academy of Sciences United States of America, 101, 10143–10148.

    Article  CAS  Google Scholar 

  16. Park, I. W., Wistuba, I. I., Maitra, A., Milchgrub, S., Virmani, A. K., Minna, J. D., et al. (1999). Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. Journal of the National Cancer Institute, 91, 1863–1868.

    Article  CAS  PubMed  Google Scholar 

  17. Maley, C. C., Galipeau, P. C., Finley, J. C., Wongsurawat, V. J., Li, X., Sanchez, C. A., et al. (2006). Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genetics, 38, 468–473.

    Article  CAS  PubMed  Google Scholar 

  18. Wistuba, I. I., Mao, L., & Gazdar, A. F. (2002). Smoking molecular damage in bronchial epithelium. Oncogene, 21, 7298–7306.

    Article  CAS  PubMed  Google Scholar 

  19. Westra, W. H. (2000). Early glandular neoplasia of the lung. Respiratory Research, 1, 163–169.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007). A translational view of the molecular pathogenesis of lung cancer. Journal of Thoracic Oncology, 2, 327–343.

    Article  PubMed  Google Scholar 

  21. Tang, X., Shigematsu, H., Bekele, B. N., Roth, J. A., Minna, J. D., Hong, W. K., et al. (2005). EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Research, 65, 7568–7572.

    CAS  PubMed  Google Scholar 

  22. Guo, M., House, M. G., Hooker, C., Han, Y., Heath, E., Gabrielson, E., et al. (2004). Promoter hypermethylation of resected bronchial margins: A field defect of changes? Clinical Cancer Research, 10, 5131–5136.

    Article  CAS  PubMed  Google Scholar 

  23. Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., et al. (2008). DNA methylation markers and early recurrence in stage I lung cancer. New England Journal of Medicine, 358, 1118–1128.

    Article  CAS  PubMed  Google Scholar 

  24. Kim, J. S., Kim, J. W., Han, J., Shim, Y. M., Park, J., & Kim, D. H. (2006). Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Research, 66, 4049–4054.

    Article  CAS  PubMed  Google Scholar 

  25. Belinsky, S. A., Klinge, D. M., Stidley, C. A., Issa, J. P., Herman, J. G., March, T. H., et al. (2003). Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research, 63, 7089–7093.

    CAS  PubMed  Google Scholar 

  26. Xu, B., Thong, N., Tan, D., & Khoury, T. (2010). Expression of thyroid transcription factor-1 in colorectal carcinoma. Applied Immunohistochemistry and Molecular Morphology, 18, 244–249.

    Article  CAS  PubMed  Google Scholar 

  27. Loo, P. S., Thomas, S. C., Nicolson, M. C., Fyfe, M. N., & Kerr, K. M. (2010). Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. Journal of Thoracic Oncology, 5, 442–447.

    Article  PubMed  Google Scholar 

  28. Ye, J., Findeis-Hosey, J. J., Yang, Q., McMahon, L. A., Yao, J. L., Li, F., et al. (2011). Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Applied Immunohistochemistry and Molecular Morphology, 19, 313–317.

    Article  CAS  PubMed  Google Scholar 

  29. Monica, V., Ceppi, P., Righi, L., Tavaglione, V., Volante, M., Pelosi, G., et al. (2009). Desmocollin-3: A new marker of squamous differentiation in undifferentiated large cell carcinoma of the lung. Modern Pathology, 22, 709–717.

    Article  CAS  PubMed  Google Scholar 

  30. Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non small-cell lung cancer. Journal of Clinical Oncology, 22, 2184–2191.

    Article  CAS  PubMed  Google Scholar 

  31. Sandler, A. B., Schiller, J. H., Gray, R., Dimery, I., Brahmer, J., Samant, M., et al. (2009). Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. Journal of Clinical Oncology, 27, 1405–1412.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Socinski, M. A., Novello, S., Brahmer, J. R., Rosell, R., Sanchez, J. M., Belani, C. P., et al. (2008). Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancer. Journal of Clinical Oncology, 26, 650–656.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., et al. (2011). International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. Journal of Thoracic Oncology, 6, 244–285.

    Article  PubMed  Google Scholar 

  34. Gorenstein, L. A., & Sonett, J. R. (2011). The surgical management of stage I and stage II lung cancer. Surgical Oncology Clinics of North America, 20, 701–720.

    Article  PubMed  Google Scholar 

  35. Wright, G., Manser, R. L., Byrnes, G., Hart, D., & Campbell, D. A. (2006). Surgery for non-small cell lung cancer: Systematic review and meta-analysis of randomised controlled trials. Thorax, 61, 597–603.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Gospodarowicz, M. K., O’Sullivan, B., & Koh, E. S. (2009). Prognostic factors: Principles and applications. In Peter Goldstraw (Ed.), IASLC Manual Staging Manual in Thoracic Oncology (pp. 111–128). Orange Park, FL: Editorial Rx Press.

    Google Scholar 

  37. Daniels, A. C. (1949). A method of biopsy useful in diagnosing certain intrathoracic diseases. Diseases of the Chest, 16, 360–367.

    Article  CAS  PubMed  Google Scholar 

  38. Carlens, E. (1959). Mediastinoscopy: A method for inspection and tissue biopsy in the superior mediastinum. Diseases of the Chest, 36, 343–352.

    Article  CAS  PubMed  Google Scholar 

  39. McNeill, T. M., & Chamberlain, J. M. (1966). Diagnostic anterior mediastinotomy. Annals of Thoracic Surgery, 2, 532–539.

    Article  CAS  PubMed  Google Scholar 

  40. Little, A. G., Rusch, V. W., Bonner, J. A., Gaspar, L. E., Green, M. R., Webb, W. R., et al. (2005). Patterns of surgical care of lung cancer patients. Annals of Thoracic Surgery, 80, 2051–2056.

    Article  PubMed  Google Scholar 

  41. Silvestri, G. A., Gould, M. K., Margolis, M. L., Tanoue, L. T., McCrory, D., Toloza, E., et al. (2007). Non-invasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132, 178S–201S.

    Article  PubMed  Google Scholar 

  42. Micames, C. G., McCrory, D. C., Pavey, D. A., Jowell, P. S., & Gress, F. G. (2007). Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. Chest, 131, 539–548.

    Article  PubMed  Google Scholar 

  43. Herth, F. J., Lunn, W., Eberhardt, R., Becker, H. D., & Ernst, A. (2005). Transbronchial versus transesophageal ultrasound-guided aspiration of enlarged mediastinal lymph nodes. American Journal of Respiratory and Critical Care Medicine, 171, 1164–1167.

    Article  PubMed  Google Scholar 

  44. Hürtgen, M., Friedel, G., Toomes, H., & Fritz, P. (2002). Radical video-assisted mediastinoscopic lymphadenectomy (VAMLA)—technique and first results. European Journal of Cardio-Thoracic Surgery, 21, 348–351.

    Article  PubMed  Google Scholar 

  45. Riaz, S. P., Linklater, K. M., Page, R., Peake, M. D., Møller, H., & Lüchtenborg, M. (2012). Recent trends in resection rates among non-small cell lung cancer patients in England. Thorax, 67, 811–814.

    Article  PubMed  Google Scholar 

  46. Lamm, D. L., Thor, D. E., Harris, S. C., Reyna, J. A., Stogdill, V. D., & Radwin, H. M. (1980). Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. Journal of Urology, 124, 38–42.

    CAS  PubMed  Google Scholar 

  47. Millar, J. W., Roscoe, P., & Pearce, S. J. (1982). Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax, 37, 57–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Patard, J. J., Saint, F., Velotti, F., Abbou, C. C., & Chopin, D. K. (1998). Immune response following intravesical bacillus Calmette-Guerin instillations in superficial madder cancer: A review. Urological Research, 26, 155–159.

    Article  CAS  PubMed  Google Scholar 

  49. Jansen, H. M., De Gast, G. C., & Esselink, M. T. (1978). Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax, 33, 429–438.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Kaufmann, M., Stjernsward, J., & Zimmermann, A. (1985). Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected Stage I and II non-small cell carcinoma of the lung. Journal of Thoracic and Cardiovascular Surgery, 89, 842–847.

    Google Scholar 

  51. O’Brien, M. E., Anderson, H., Kaukel, E., O’Byrne, K., Pawlicki, M., Von Pawel, J., et al. (2004). SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Annals of Oncology, 15, 906–914.

    Article  PubMed  Google Scholar 

  52. Stanford, J. L., Stanford, C. A., O’Brien, M. E., & Grange, J. M. (2008). Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. European Journal of Cancer, 44, 224–227.

    Article  CAS  PubMed  Google Scholar 

  53. Forero, A., Meredith, R. F., Khazaeli, M. B., Shen, S., Grizzle, W. E., Carey, D., et al. (2005). Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration. Cancer Biotherapy and Radiopharmaceuticals, 20, 467–478.

    Article  CAS  PubMed  Google Scholar 

  54. Grant, S. C., Kris, M. G., Houghton, A. N., & Chapman, P. B. (1999). Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clinical Cancer Research, 5, 1319–1323.

    CAS  PubMed  Google Scholar 

  55. Hernández, A. M., Toledo, D., Martínez, D., Griñán, T., Brito, V., Macías, A., et al. (2008). Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. The Journal of Immunology, 181, 6625–6634.

    Article  PubMed  Google Scholar 

  56. Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., et al. (2006). Trastuzumab based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? British Journal of Cancer, 94, 259–267.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Maulik, G., Kijima, T., & Salgia, R. (2003). Role of receptor tyrosine kinases in lung cancer. Methods in Molecular Medicine, 74, 113–125.

    CAS  PubMed  Google Scholar 

  58. Grotzinger, J. (2002). Molecular mechanisms of cytokine receptor activation. Biochimica et Biophysica Acta, 1592, 215–223.

    Article  CAS  PubMed  Google Scholar 

  59. Pawson, T. (2002). Regulation and targets of receptor tyrosine kinases. European Journal of Cancer, 38(Suppl 5), S3–S10.

    Article  PubMed  Google Scholar 

  60. Hirsch, F. R., Scagliotti, G. V., Langer, C. J., Varella-Garcia, M., & Franklin, W. A. (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies. Lung Cancer, 41(Suppl 1), S29–S42.

    Article  PubMed  Google Scholar 

  61. Levitzki, A. (2003). EGF receptor as a therapeutic target. Lung Cancer, 41(Suppl 1), S9–S14.

    Article  PubMed  Google Scholar 

  62. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., et al. (2002). Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacology and Therapeutics, 93, 79–98.

    Article  CAS  PubMed  Google Scholar 

  63. Davies, A. M., Gandara, D. R., Lara, P. N, Jr, Mack, P. C., Lau, D. H., & Gumerlock, P. H. (2003). Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clinical Lung Cancer, 4(Suppl 2), S68–S73.

    Article  PubMed  Google Scholar 

  64. Tong, A. W., Zhang, Y. A., Cunningham, C., Maples, P., & Nemunaitis, J. (2001). Potential clinical application of antioncogene ribozymes for human lung cancer. Clinical Lung Cancer, 2, 220–226.

    Article  CAS  PubMed  Google Scholar 

  65. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences United States of America, 98, 13790–13795.

    Article  CAS  Google Scholar 

  66. Meyerson, M., & Carbone, D. (2005). Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy. Journal of Clinical Oncology, 23, 3219–3226.

    Article  CAS  PubMed  Google Scholar 

  67. Chen, H. Y., Yu, S. L., Chen, C. H., Chang, G. C., Chen, C. Y., Yuan, A., et al. (2007). A five-gene signature and clinical outcome in non-small-cell lung cancer. New England Journal of Medicine, 356, 11–20.

    Article  CAS  PubMed  Google Scholar 

  68. Patz, E. F, Jr, Campa, M. J., Gottlin, E. B., Kusmartseva, I., Guan, X. R., & Herndon, J. E, I. I. (2007). Panel of serum biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology, 25, 5578–5583.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun, 130033, Jilin, China

    Haixiang Yu, Zhenguo Han, Yue Wang & Hua Xin

Authors
  1. Haixiang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenguo Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hua Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Xin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, H., Han, Z., Wang, Y. et al. The Clonal Evolution and Therapeutic Approaches of Lung Cancer. Cell Biochem Biophys 70, 63–71 (2014). https://doi.org/10.1007/s12013-014-9910-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-9910-y

Keywords

Search

Navigation